Wolfgang Jungraithmayr | Medicine and Dentistry | Lifetime Achievement Award

Posted on by Phenomenological Research

Lifetime Achievement Award

Wolfgang Jungraithmayr
University Hospital of Rostock, Germany

Wolfgang Jungraithmayr
Researcher Wolfgang Jungraithmayr
Affiliation University Hospital of Rostock
Country Germany
Scopus ID 25621008100
Documents 129
Citations 2,929
h-index 28
Subject Area Medicine and Dentistry
Event International Phenomenological Research Awards
ORCID 0000-0002-1442-4862

Wolfgang Jungraithmayr, MD, PhD, is a German thoracic surgeon, clinician-scientist, educator, and academic leader serving as Chair and Full Professor of Thoracic Surgery at the University Hospital of Rostock. His research portfolio spans lung transplantation, thoracic oncology, immunology, translational medicine, and experimental surgery. He is particularly recognized for pioneering the orthotopic mouse lung transplantation model and for advancing translational research into lung cancer immunotherapy and transplant immunology.[1]

Abstract

This article evaluates the scholarly achievements, research leadership, educational contributions, and international influence of Wolfgang Jungraithmayr in the fields of thoracic surgery, lung transplantation, and translational oncology. His work integrates clinical practice with experimental science, contributing to advances in transplant immunology, lung cancer therapeutics, and surgical innovation. Through sustained research productivity, competitive grant acquisition, international collaboration, and extensive scientific mentorship, he has established a distinguished academic profile suitable for consideration for lifetime recognition within the biomedical sciences.[1]

Keywords

Thoracic Surgery; Lung Transplantation; Lung Cancer; Immunology; Translational Medicine; CD26; Experimental Surgery; Academic Leadership; Oncology; Lifetime Achievement.

Introduction

Wolfgang Jungraithmayr has developed an interdisciplinary academic career combining thoracic surgical practice, translational biomedical research, and university-level education. Following medical training in Germany and advanced specialization in Switzerland, he completed doctoral research in immunology at the University and ETH Zurich. His subsequent appointments included leadership positions at the University Hospital Zurich, Medical University Brandenburg, and University Hospital Rostock, where he currently serves as Chair of Thoracic Surgery.[2]

His scientific activities have focused on improving outcomes in lung transplantation, understanding immune-mediated disease mechanisms, and identifying novel therapeutic targets for thoracic malignancies. These efforts have produced a substantial body of peer-reviewed literature and attracted significant competitive funding from European research agencies.[1]

Research Profile

Wolfgang Jungraithmayr’s research program centers on lung transplantation biology, transplant tolerance, tumour immunology, and translational thoracic oncology. A major contribution of his laboratory has been the establishment and dissemination of the orthotopic mouse lung transplantation model, which has become a valuable experimental platform for investigating immune responses, rejection mechanisms, and therapeutic interventions across multiple disciplines.[3]

His laboratory has secured more than €3.2 million in competitive research funding, including support from the German Research Foundation (DFG), Swiss National Science Foundation (SNSF), and other major funding bodies. Research projects have addressed chronic lung allograft dysfunction, immune regulation, magnetic resonance imaging applications, angiogenesis, and targeted immunotherapeutic approaches against lung adenocarcinoma.[1]

Research Contributions

Wolfgang Jungraithmayr’s principal research contributions include pioneering murine lung transplantation models, advancing transplant immunology, investigating immune tolerance mechanisms, identifying novel therapeutic targets in lung cancer, and improving understanding of ischemia-reperfusion injury and chronic allograft dysfunction.[2][4][5][6]

Publications

Recent publications highlight Jungraithmayr’s contributions to transplantation immunology, lung transplant outcomes, ischemia-reperfusion injury, and experimental models of chronic allograft dysfunction, demonstrating sustained impact in thoracic surgery and translational research.[2][3][4][5][6]

Wolfgang Jungraithmayr has authored more than 160 scientific publications and maintains a sustained record of peer-reviewed research. Representative publications reflect his contributions to lung transplantation, transplant immunology, and thoracic oncology.[1]

Research Impact

According to Scopus metrics, Jungraithmayr has accumulated 129 indexed documents, 2,929 citations, and an h-index of 28. These indicators demonstrate sustained scholarly influence within thoracic surgery, transplantation science, and oncology research.[1]

Beyond publication metrics, his impact is reflected through international teaching initiatives, reviewer responsibilities for leading journals, grant-review service for major funding agencies, editorial board memberships, and mentorship of emerging clinicians and scientists. His laboratory has trained investigators from numerous institutions across Europe, North America, and Asia, thereby extending the global reach of his methodological innovations.[1]

Award Suitability

Several factors support consideration of Wolfgang Jungraithmayr for a Lifetime Achievement Award. These include his longstanding record of scientific productivity, leadership of internationally recognized research programs, establishment of innovative experimental models, successful acquisition of competitive funding, extensive educational activities, and receipt of numerous international scientific distinctions. His contributions have influenced both clinical practice and experimental biomedical research, particularly in thoracic surgery and transplantation science.[1]

The cumulative scope of his achievements illustrates a sustained commitment to advancing medical knowledge, supporting scientific collaboration, and fostering the development of future generations of clinician-scientists.[2]

Conclusion

Wolfgang Jungraithmayr represents a notable figure in contemporary thoracic surgery and translational medicine. Through pioneering research, academic leadership, international educational engagement, and sustained scientific productivity, he has contributed significantly to the advancement of lung transplantation and thoracic oncology. His record of achievement, influence, and service provides a strong basis for recognition within the framework of a Lifetime Achievement Award.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: Wolfgang Jungraithmayr, Author ID 25621008100. Scopus. https://www.scopus.com/authid/detail.uri?authorId=25621008100
  2. Ohm B, Giannou AD, Harriman DI, Jungraithmayr WM, Zazara DE, et al. (2025). Chimerism and Immunological Tolerance in Solid Organ Transplantation. Immunologic Research. https://link.springer.com/article/10.1007/s00281-025-01052-x
  3. Moneke I, Ogutur ED, Kornyeva A, Jungraithmayr WM, Frye BC, et al. (2024). Donor Age Over 55 Is Associated With Worse Outcome in Lung Transplant Recipients With Idiopathic Pulmonary Fibrosis. BMC Pulmonary Medicine, 2024. https://link.springer.com/article/10.1186/s12890-024-03317-x
  4. Sander ML, Eulenburg V, Maeyashiki T, Jungraithmayr WM, Piegeler T, et al. (2024). Remote Kidney and Liver Injury After Transplantation of Lung Allografts in an Allogeneic Mouse Model. Transplantation Proceedings, 2024. DOI: https://doi.org/10.1016/j.transproceed.2024.10.020
  5. Coppens A, Verleden SE, Claes E, Voet H, Verleden GM, Lapperre TS, Yildirim AÖ, et al. (2024). Murine Orthotopic Lung Transplant Models: A Comprehensive Overview of Genetic Mismatch Degrees and Histopathological Insights Into Chronic Lung Allograft Dysfunction. American Journal of Transplantation, 2024. DOI: https://doi.org/10.1016/j.ajt.2024.07.033
  6. Jungraithmayr W. (2020). Novel Strategies for Endothelial Preservation in Lung Transplant Ischemia-Reperfusion Injury. Frontiers in Physiology, 2020. DOI: https://doi.org/10.3389/fphys.2020.581420

Qizhi Diao | Medicine and Dentistry | Research Excellence Award

Posted on by Phenomenological Research

Research Excellence Award

Qizhi Diao
Hainan Branch, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, China
Qizhi Diao
Affiliation Shanghai Jiao Tong University
Country China
Designation Professor
Scopus ID 52563308500
Documents 19
Citations 252
h-index 9
Subject Area Medicine and Dentistry
Event International Phenomenological Research Awards
ORCID 0000-0003-1121-4656

Qizhi Diao is a professor affiliated with the Hainan Branch of Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Sanya, China. His academic work has focused on the synthesis of functional nanomaterials, the construction of advanced clinical diagnostic sensors, and the development of nanocarrier-mediated therapeutic systems for biomedical applications. His research activities have contributed to innovations in biosensing technologies, point-of-care diagnostics, CRISPR/Cas-enabled sensing systems, and nanopharmaceutical delivery platforms.[1] Diao has participated in multiple nationally and provincially funded scientific projects related to cancer diagnostics, SARS-CoV-2 detection technologies, and exosome identification systems within nucleic acid assembly frameworks.[2]

Abstract

The academic contributions of Qizhi Diao are associated with interdisciplinary developments in nanomedicine, biosensor engineering, and clinical laboratory technologies. His research has emphasized the design of graphdiyne-based nanostructures, electrochemical sensing systems, nanozyme-assisted diagnostics, and portable point-of-care biosensing platforms. Through projects supported by the National Natural Science Foundation of China and regional scientific agencies, Diao has contributed to the development of technologies for detecting infectious diseases, circulating tumor cells, and gastric cancer biomarkers.[3] His work integrates materials science, clinical diagnostics, and biomedical engineering into translational research frameworks applicable to modern laboratory medicine.

Keywords

Nanomaterials; Graphdiyne; Clinical Diagnostic Sensors; CRISPR/Cas Technology; Electrochemical Biosensors; Nanopharmaceuticals; Targeted Drug Delivery; Nanozymes; Medical Laboratory Technology; Point-of-Care Diagnostics; Biomedical Engineering; Electrochemical Sensing.

Introduction

Recent advancements in biomedical engineering and nanotechnology have accelerated the development of highly sensitive diagnostic platforms and targeted therapeutic systems. Within this scientific context, Qizhi Diao has conducted research aimed at integrating nanomaterial synthesis with clinical laboratory applications. His work has addressed major challenges in biosensing accuracy, rapid pathogen detection, and nanocarrier-mediated therapeutic delivery systems.[4]

Qizhi Diao’s investigations into graphdiyne-based sensing systems and nanozyme catalytic materials have contributed to the broader understanding of electrochemical diagnostics and biosensor miniaturization. His projects have also focused on CRISPR/Cas-mediated detection systems capable of improving diagnostic sensitivity for infectious diseases and cancer-associated biomarkers.[5]

Research Profile

Qizhi Diao has maintained a long-term academic focus on the fabrication of functional nanomaterials, clinical diagnostic sensors, and nanocarrier-mediated drug delivery systems. His institutional affiliations include the Hainan Branch of Shanghai Children’s Medical Center and Shanghai Jiao Tong University School of Medicine.[1]

His completed and ongoing projects include:

  • Research on encoding for the identification of plasma exosome subtypes based on confined recognition and amplification systems within nucleic acid assembly frameworks funded by the National Natural Science Foundation of China.
  • Portable sensors for simultaneous detection of multiple gastric cancer biomarkers using CRISPR/Cas technology funded by the Hainan Provincial Health Commission.
  • Point-of-care quantitative detection systems for SARS-CoV-2 nucleic acids using graphdiyne sub-nanosheets supported by the Natural Science Foundation Project of Chongqing.
  • Novel 3D magnetic nanocomposites based on graphdiyne-MOFs for simultaneous capture and chemotherapy of circulating tumor cells in peripheral blood.
  • Development of graphdiyne-based systems for the detection of SARS-CoV-2 antigen biomarkers under emergency biomedical research initiatives.

His scientific profile additionally includes responsibilities as an ISO 15189 medical laboratory accreditation assessor and research review expert for multiple scientific organizations and governmental institutions in China.[6]

Research Contributions

Among Qizhi Diao’s reported scientific contributions is the synthesis of sub-nanoscale graphdiyne materials for the rapid and quantitative detection of Mycobacterium tuberculosis and drug-resistant genes.[7] This work supported the development of fluorescence sensing systems with improved analytical sensitivity and operational simplicity.

He also contributed to the preparation of core-shell nanozymes such as ZrFe-MOF@PtSn exhibiting strong peroxidase-like catalytic properties for biosensing applications. Additionally, his research integrated miRNA-initiated strand displacement amplification with CRISPR/Cas12a amplification strategies, nanozyme catalysis, and machine-learning-assisted electrochemical sensing systems.[8]

Qizhi Diao has further contributed to patents related to electrochemical immunosensors, medical testing oscillation devices, and laboratory inspection equipment. These developments reflect the translational dimension of his work in clinical laboratory technologies.[9]

Publications

Qizhi Diao has published research in internationally recognized journals focusing on nanotechnology, biomedical sensing, and clinical diagnostic systems. His publications explore graphdiyne-based fluorescent sensing platforms for detecting Mycobacterium tuberculosis and drug-resistant genes, nanoparticle-based drug delivery systems for cardiovascular diseases, and nanozyme-assisted biosensing technologies for rapid pathogen detection. He has also contributed to studies on high-porosity carbon electrocatalysts and amino-functionalized carbon nanodots for biomedical applications. His scholarly work integrates nanomaterials, electrochemical sensing, CRISPR/Cas technologies, and translational laboratory medicine, supporting advancements in point-of-care diagnostics, targeted therapeutics, and innovative clinical biosensor development.

Research Impact

The research activities of Qizhi Diao have contributed to interdisciplinary developments linking nanotechnology, laboratory medicine, and biomedical sensing systems. His work on graphdiyne nanostructures and nanozyme catalytic platforms has been associated with improved biosensor sensitivity and enhanced diagnostic performance in infectious disease detection.[10]

According to the provided academic indicators, his research record includes an h-index of 9 and more than 252 citations indexed through Scopus, in addition to reported Web of Science citations exceeding 300.[11] His collaborative work with organizations such as the Chinese Medical Doctor Association and the Chinese Medical Association has also supported laboratory medicine standardization and diagnostic research initiatives.

Award Suitability

The academic profile of Qizhi Diao demonstrates sustained engagement in translational biomedical research, particularly within nanomaterials, biosensors, and clinical diagnostics. His involvement in nationally funded scientific projects, patented technologies, and peer-reviewed publications indicates an active contribution to applied medical research and laboratory innovation.

His combination of scientific output, technical expertise, research leadership, and participation in accreditation and evaluation activities supports consideration for the Research Excellence Award under the International Phenomenological Research Awards framework.

Conclusion

Qizhi Diao has contributed to the advancement of nanotechnology-enabled diagnostic systems and biomedical sensing platforms through interdisciplinary scientific research. His work combines materials engineering, electrochemical sensing, nanozyme catalysis, and clinical laboratory applications into translational biomedical solutions. Through publications, funded research projects, patents, and scientific service roles, he has established a research profile connected to contemporary developments in medical diagnostics and nanomedicine.

References

  1. International Phenomenological Research Awards. (2026). Award nomination application form: Qizhi Diao. https://phenomenologicalresearch.com/
  2. National Natural Science Foundation of China. Research project information related to biomedical sensing and exosome identification systems.
  3. Diao Q. Research projects and biomedical sensing technologies associated with clinical diagnostics and nanomaterials research.
  4. Shanghai Jiao Tong University School of Medicine. Biomedical nanotechnology and laboratory medicine research activities.
  5. CRISPR/Cas biosensing applications in rapid diagnostic systems and molecular detection technologies.
  6. China National Accreditation Service for Conformity Assessment (CNAS). ISO 15189 medical laboratory accreditation activities and technical assessment programs.
  7. Chang F, Huang L, Guo C, Xie G, Li J, Diao Q. (2019). Graphdiyne-Based One-Step DNA Fluorescent Sensing Platform for the Detection of Mycobacterium tuberculosis and Its Drug-Resistant Genes. ACS Applied Materials & Interfaces. https://pubs.acs.org/doi/abs/10.1021/acsami.9b15248
  8. Yang F, Xue J, Wang G, Diao Q. (2022). Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2022.999404
  9. Chinese patent documentation related to electrochemical immunosensors, laboratory inspection devices, and medical testing technologies.
  10. Feng T, Liao W, Li Z, Sun L, Shi D, Guo C, Huang Y, Wang Y, Cheng J, Li Y, Diao Q. (2017). Heavily Graphitic-Nitrogen Self-doped High-porosity Carbon for the Electrocatalysis of Oxygen Reduction Reaction. Nanoscale Research Letters. https://link.springer.com/article/10.1186/s11671-017-2364-6
  11. Elsevier. (n.d.). Scopus author details: Qizhi Diao, Author ID 52563308500. Scopus. https://www.scopus.com/authid/detail.uri?authorId=52563308500

Franziska Münz | Medicine and Dentistry | Future Science Leader Award

Posted on by Phenomenological Research

Dr. Franziska Münz | Medicine and Dentistry | Future Science Leader Award 

Physician at Universität Heidelberg | Germany

Dr. Franziska Münz is a promising researcher in the field of Medicine and Dentistry, demonstrating strong scientific impact through 10 scholarly documents that have collectively received 97 citations across 88 academic works, alongside an h-index of 5. Her research contributions focus on advancing medical knowledge through evidence-based approaches, particularly in clinically relevant and translational domains. Her work reflects a commitment to improving healthcare outcomes by exploring innovative methodologies and interdisciplinary perspectives. With a growing citation record and consistent publication output, Dr. Franziska Münz shows clear potential as an emerging leader in future scientific advancements. Her research trajectory highlights both quality and influence, positioning her as a valuable contributor to the global medical research community and a strong candidate for recognition under the Future Science Leader Award.

Citation Metrics

100

75

50

25

0

Citations
97

Documents
10

h-index
5

View Scopus Profile

Top 5 Publications

Iker Alonso González | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research

Mr. Iker Alonso González | Medicine and Dentistry | Best Researcher Award 

FACULTATIVO ESPECIALISTA MEDICO-TECNICO EN MICROBIOLOGÍA Y PARASITOLOGÍA at Cruces University Hospital | Spain

Mr. Iker Alonso González is a dedicated researcher and professional in the field of microbiology and clinical parasitology, recognized for his growing contributions to medical and pharmaceutical sciences. He holds a degree in Pharmacy from the University of the Basque Country (UPV/EHU) and has further specialized in Microbiology and Clinical Parasitology at Cruces University Hospital, where he continues to advance his expertise in infectious disease research and diagnostics. His professional experience at Osakidetza the Basque Health Service combines clinical practice with applied research, focusing on microbial resistance, infectious disease control, and antibiotic stewardship. He has presented numerous research communications, including fourteen posters and two oral presentations at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), addressing critical topics such as antimicrobial resistance patterns in Shigella spp. and the clinical impact of post-treatment uroculture interventions. His scientific publication, “Multiresistant Aeromonas hydrophila bacteremia,” published in Enferm Infecc Microbiol Clin (Engl Ed), reflects his analytical approach and contribution to understanding emerging multidrug-resistant pathogens. His current research interests center around the development of evidence-based antimicrobial protocols, optimization of laboratory diagnostics, and epidemiological monitoring of infectious diseases in clinical settings. Mr. Iker Alonso González’s participation in national research forums and professional societies highlights his commitment to academic collaboration and scientific advancement. His early scholarly impact is reflected in his record of 2 citations by 2 documents, 3 published works, and an h-index of 1, indicating a promising trajectory in medical research. He is also engaged in continuous professional development, ensuring alignment with global standards in clinical microbiology and pharmaceutical practice. Through his rigorous research, clinical application, and scholarly engagement, Mr. Iker Alonso González exemplifies the integration of scientific inquiry and healthcare innovation, contributing to the ongoing efforts to enhance antimicrobial stewardship and patient outcomes in contemporary medicine.

Profile: Scopus

Featured Publications:

  • Alonso-González, I. (2025). Upper limb abscess due to an unusual Clostridium species in an immunocompetent child. Enfermedades Infecciosas y Microbiología Clínica.

  • Alonso-González, I. (2023). Sensitivity profile of Shigella spp. isolates in patients with travelers’ diarrhea in a tertiary hospital in the period 2017–2022. Presented at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

  • Alonso-González, I. (2023). Impact of a PROA intervention on the request of non-proven post-treatment control urocultures. Presented at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

  • Alonso-González, I. (2022). Multiresistant Aeromonas hydrophila bacteremia. Enfermedades Infecciosas y Microbiología Clínica